Wegovy (Semaglutide Weight Management)

Wegovy (Semaglutide Weight Management) is filed as GLP-1 Receptor Agonist. The sections below restate public label fields stored for this profile.

Class
GLP-1 Receptor Agonist
Generic name
Semaglutide Weight Management
Route
SUBCUTANEOUS
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Injection: clear, colorless solution supplied in prefilled, single-dose pens in the following strengths: • 0.25 mg/0.5 mL • 0.5 mg/0.5 mL • 1 mg/0.5 mL • 1.7 mg/0.75 mL • 2.4 mg/0.75 mL • 7.2 mg/0.75 mL (WEGOVY HD) Tablets: white to light yellow, round shaped debossed with the strength on one side and “novo” on the other side: • 1.5 mg • 4 mg • 9 mg Tablets: white to light yellow, oval shaped debossed with the strength on one side and “novo” on the other side: • 25 mg • Injection: prefilled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg , 2.4 mg or WEGOVY HD 7.2 mg ( 3 ) • Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg ( 3 )
Generic available
No
Manufacturer
Novo Nordisk
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity. o Adults with overweight in the presence of at least one weight-related comorbid condition. • For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies ( 14.4 )] . Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) • for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies ( 14.4 )] . Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. ( 1 ) WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: • Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 )

How it works

12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake. The exact mechanism of semaglutide in CV risk reduction in adults has not been established. For treatment of MASH in humans, the precise mechanism of action of semaglutide is not fully understood and may involve multiple pathways mediated by weight loss and other factors. In a mouse model of diet-induced MASH, treatment with semaglutide resulted in histological improvements in steatosis, inflammation, and fibrosis in liver compared to baseline, which was associated with body weight loss, intermittent periods of reduced food intake, and improvements in relevant biomarkers. The relationship between the pathophysiology of MASH in animal models and humans has not been fully established.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. ( 5.1 , 13.1 ) • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. ( 4 , 5.1 )

Warnings and precautions

BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. ( 5.1 , 13.1 ) • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. ( 4 , 5.1 )

Contraindications

4 CONTRAINDICATIONS WEGOVY is contraindicated in the following conditions: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY [see Warnings and Precautions ( 5.7 )] . • Personal or family history of MTC or in patients with MEN 2. ( 4 ) • Known hypersensitivity to semaglutide or any of the excipients in WEGOVY tablets or WEGOVY injection. ( 4 )

Common side effects

Nausea (44%); Diarrhea (30%); Vomiting (24%); Constipation (24%); Abdominal pain (20%); Headache (14%); Fatigue (11%); Dyspepsia (9%); Dizziness (8%); Abdominal distension (7%); Eructation (7%); Flatulence (6%); Gastroenteritis (6%); Gastroesophageal reflux disease (5%)

Adverse reactions

The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-Cell Tumors [see Warnings and Precautions ( 5.1 )] • Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] • Acute Gallbladder Disease [see Warnings and Precautions ( 5.3 )] • Hypoglycemia [see Warnings and Precautions ( 5.4 )] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.7 )] • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions ( 5.8 )] • Heart Rate Increase [see Warnings and Precautions ( 5.9 )] • Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )]

Dosage and administration

2.1 Important Administration Instructions • Administer WEGOVY subcutaneously once weekly, on the same day each week, at any time of day, with or without meals. • Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose. • The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 48 hours. 2.2 Recommended Dosage in Adult Patients • Initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly. Over a 16-week period, escalate the dosage as shown below to reach the maintenance dosage of 2.4 mg once weekly. Dose-escalation schedule (adults): • Weeks 1–4: 0.25 mg once weekly • Weeks 5–8: 0.5 mg once weekly • Weeks 9–12: 1 mg once weekly • Weeks 13–16: 1.7 mg once weekly • Week 17 onward (maintenance): 2.4 mg once weekly • If patients do not tolerate the maintenance 2.4 mg dosage, the dosage can be temporarily decreased to 1.7 mg once weekly for a maximum of 4 weeks. After 4 weeks, increase to the maintenance 2.4 mg once weekly. Discontinue WEGOVY if the patient cannot tolerate the 2.4 mg dosage. 2.3 Recommended Dosage in Pediatric Patients 12 Years and Older • Initiate at 0.25 mg once weekly and follow the same escalation schedule as adults to the maintenance dosage of 2.4 mg once weekly. • If the 2.4 mg maintenance dosage is not tolerated, decrease to 1.7 mg once weekly. Patients who cannot tolerate 1.7 mg once weekly should discontinue WEGOVY. 2.4 Missed Dose • If a dose is missed and the next scheduled dose is more than 48 hours away, administer as soon as possible. • If less than 48 hours remain before the next scheduled dose, skip the missed dose and take the next dose on the regularly scheduled day. • If more than two consecutive weekly doses are missed, consider reinitiating with a lower dose and re-escalating, which may reduce gastrointestinal symptoms.

Drug interactions

7 DRUG INTERACTIONS WEGOVY delays gastric emptying. May impact absorption of concomitantly administered oral medications. Consider increased clinical or laboratory monitoring when used concomitantly with other oral medications that have a narrow therapeutic index or that require clinical monitoring. ( 7.2 ) 7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea) WEGOVY lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). The addition of WEGOVY in patients treated with insulin has not been evaluated. When initiating WEGOVY, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6.1 )] . 7.2 Oral Medications WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications [see Clinical Pharmacology ( 12.3 )] . In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY. Consider increased clinical or laboratory monitoring for medications that have a narrow therapeutic index or that require clinical monitoring.

Common questions

What is Wegovy approved to treat?

According to its FDA label, Wegovy (Semaglutide Weight Management) is approved for: 1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with estab… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Wegovy?

Wegovy (Semaglutide Weight Management) belongs to the GLP-1 Receptor Agonist class of medications.

What form does Wegovy come in?

The FDA label lists Wegovy (Semaglutide Weight Management) as: 3 DOSAGE FORMS AND STRENGTHS Injection: clear, colorless solution supplied in prefilled, single-dose pens in the following strengths: • 0.25 mg/0.5 mL • 0.5 mg/0.5 mL • 1 mg/0.5 mL • 1.7 mg/0.75 mL • 2.4 mg/0.75 mL • 7.2 mg/0.75 mL (WEGOVY HD) Tablets: white to light yellow, round shaped debossed with the strength on one side and “novo” on the other side: • 1.5 mg • 4 mg • 9 mg Tablets: white to light yellow, oval shaped debossed with the strength on one side and “novo” on the other side: • 25 mg • Injection: prefilled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg , 2.4 mg or WEGOVY HD 7.2 mg ( 3 ) • Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg ( 3 ); subcutaneous route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Wegovy?

Not yet. As of the most recent FDA data we ingest, no A-rated generic equivalent is listed for Wegovy. Availability changes as patents expire.

Does Wegovy have a Boxed Warning?

Yes. The FDA label for Wegovy (Semaglutide Weight Management) carries a Boxed Warning. Excerpt: "WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Wegovy cost?

Public CMS NADAC pricing for Wegovy (Semaglutide Weight Management) is in the range $1,300–$1,500/month. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Wegovy currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Wegovy (Semaglutide Weight Management) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Wegovy approved by the FDA?

The FDA record lists the approval date for Wegovy (Semaglutide Weight Management) as 2025-12-22.

Who makes Wegovy?

The FDA label lists Novo Nordisk as a labeler/manufacturer of Wegovy (Semaglutide Weight Management). Multiple firms may market generics of the same molecule.

How should Wegovy be stored?

The FDA label states: "Store new (unused) WEGOVY pens in a refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze. Do not use if it has been frozen. • Keep the pen in the original carton to protect from light until time of use. • If nee…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…